期刊文献+

肾肉瘤样癌1例临床分析并文献复习 被引量:1

暂未订购
导出
摘要 [目的]探讨肾肉瘤样癌的临床及病理特点,提高对其的诊治水平.[方法]报告1例肾肉瘤样癌患者的临床及病理资料,复习相关文献进行讨论.[结果]患者临床表现有肉眼血尿、消廋、乏力等.术后病理检查见上皮和肉瘤样间质两种恶性成分,免疫组化染色癌组织角蛋白(CK) 阳性,上皮膜抗原(EMA)阳性.患者术后4个月死于远处转移、全身衰竭.[结论]肾肉瘤样癌具有浸润性生长的生物学特性,恶性程度高,预后差.确诊依赖病理学及免疫组化检查 化疗、放疗都不敏感,根治性切除手术仍是首选治疗方式.
出处 《医学临床研究》 CAS 2011年第2期310-312,共3页 Journal of Clinical Research
关键词 癌肉瘤 肾肿瘤
  • 相关文献

参考文献15

  • 1Ro JY,Ayala AG,SeIla A, et al . Sarcomatoid renal cell earci- noma:A clinicopathologic study of 42 cases[J]. Cancer , 1987 ,59 (3) :516-526.
  • 2Cheville ,John C ,Lohse, el al . Sarcomatoid Renal Cell Carcinoma : An Examination of Underlying Histologic Subtype and an Analysis of Associations Wilh Patient Outeome[J]. Am J Sure Pathol ,2004 ,28 (4) :435-441.
  • 3王伟,王晓雄.CT对肾癌诊断和分期的价值[J].中华泌尿外科杂志,1998,19(4):205-207. 被引量:3
  • 4李泉林,关宏伟,张秋萍,薛军,王法鹏,高鹤立,韩辉,张仁科.肾癌多中心病灶发生机理的探讨[J].中华泌尿外科杂志,2003,24(4):232-234. 被引量:30
  • 5Peraha Venturina M, Moch H, Amin M, et al . Sarcomatoid differentiation in renal cell carcinoma[J]. AmJ Surg Pathol , 2001,25 (3) :275-284.
  • 6Hes O ,Curik R, Malatkova V, el al . Metanephric adenoma and papillary carclnoma with sareomatoid dedifferentiation of kidney : a case report[J]. Patkol Res Pracl ,2003 ,199 (9) :629-632.
  • 7张哉根,叶明福,谢青,王亚丽,汤金梁.肉瘤样癌的病理诊断与鉴别诊断研究[J].第三军医大学学报,2002,24(8):958-960. 被引量:41
  • 8Tomoo I ,Kanako C , Satoshi O, et al . Chromophobe renal cell carcinoma with osteosarcoma - like differentiation[J]. Am J Sur,q Pathol ,2002, 26(10) :1358-1362,.
  • 9Deyrup AT , Montgomery E , Fisher C. Leiomyosarcoma of the kidney : a clinicopathologic study [J]. Am J Surg Pathol ,2004 ,28(2) :178-182.
  • 10侯德法,孟刚,郝大海.肉瘤样癌形态学及免疫组化观察[J].安徽医科大学学报,2008,43(6):627-630. 被引量:28

二级参考文献30

  • 1徐美清,梅新宇,魏大中,范军,朱晓枫.肺癌肉瘤的临床观察[J].安徽医科大学学报,2004,39(4):319-320. 被引量:6
  • 2赵尔增,张建中,郑燕华,张铭.食管肉瘤样癌临床病理和免疫组化分析[J].肿瘤防治杂志,2004,11(12):1304-1306. 被引量:3
  • 3兰玉华,熊红梅,李捷艳.十二指肠降部癌肉瘤1例[J].诊断病理学杂志,2006,13(1):51-51. 被引量:4
  • 4曹智,张洵,苏勤,杨琳,孙耘田.结肠肉瘤样癌的组织学及免疫组化观察[J].诊断病理学杂志,2006,13(3):202-204. 被引量:9
  • 5[1]Nathan P,Chao D,Brock C,et al.The place of VEGF inhibition in the current management of renal cell carcinoma.Br J Cancer,2006,94 (9):1217
  • 6[2]Hainsworth D,Sosman J A,Spigel D R,et al.Phase Ⅱ trial of bevacizumab and erlotinib in patients with metastatic renal carcinoma (RCC).J Clin Oncol (Meeting Abstracts),2004,22:4502.
  • 7[3]Robert J.Motzer,M Dror Michaelson,Bruce G Redman,et al.Activity of SU11248,a multitargeted inhibitor or vascular endothelial growth factor receptor and platelet-derived growth factor receptor,in patients with metastatic renal cell carcinoma.J Clin Oncol,2006,24:16
  • 8[4]Eisen T,Bukowski R M,Staehler M,et al.Randomized phase Ⅲ trial of sorafenib in advanced renal cell carcinoma (RCC):Impact of crossover on survival.J Clin Oncol (Meeting Abstracts),2006,24:4524
  • 9[5]Ryan C W,Goldman B H,Lara P N,et al.Sorafenib plus interferon-2b (IFN) as first-line therapy for advanced renal cell carcinoma (RCC):SWOG 0412.J Clin Oncol (Meeting Abstracts),2006,24:4525
  • 10[6]Tamaskar Ⅰ,Shaheen P,Wood L,et al.Antitumor effects of sorafenib and sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC) who had prior therapy with anti-angiogenic agents,J Clin Oncol (Meeting Abstracts),2006,24:4597.

共引文献92

同被引文献8

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部